… In this trial (NCT04746183) we evaluated the safety and optimal dose of molnupiravir in …
of molnupiravir in human patients, including studies to define the appropriate dose for a human …

… safety and optimal dose of molnupiravir in participants with … patients in the study arm. aDate
of randomization is the same as date of first dose for all patients randomized to molnupiravir. …

… Among patients aged 65 and above they found that molnupiravir reduced the risk of …
the use of molnupiravir in hospitalized patients. Wong et al. compared 1856 patients without …

… receiving molnupiravir were used to make the dose escalation decision. The dose levels …
protocol to FDA for a study of molnupiravir in patients with symptomatic COVID-19 not requiring …

… efficacy and safety of molnupiravir in patients with COVID-19. … molnupiravir were used except
for single ascending doses where an oral solution was used for flexibility in dose escalation…

… in an outpatient setting, patients with risk factors including … are heavily skewed toward older
patients and those with risk … ) were reviewed prior to each dose escalation to ensure that …

… (n = 130) to find out the safety and dosing range of Molnupiravir. It was found safe and well
… which was a Phase Ib/IIa dose escalation study conducted in eighteen COVID-19 patients. …

… established in vaccinated patients in the community at increased risk of morbidity and mortality
from COVID-19. We aimed to establish whether the addition of molnupiravir to usual care …

… of molnupiravir dosed twice daily (BID) for 5 days in patients with mild-to-moderate COVID-19.
Hypotheses included that molnupiravir … escalation as clinical development of molnupiravir …

… In addition, molnupiravir therapy completely blocked SARS-CoV-2 transmission to … We
believe that early molnupiravir treatment in asymptomatic or mildly symptomatic patients can …